Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Press Release : New Roche data at 2021 AAN -3-

04/08/2021 | 01:00am EDT
MS [SPMS], in addition to clinically isolated syndrome [CIS] in the 
U.S.) and PPMS. At Roche, we are constantly striving to optimise the 
care for people with MS and a shorter two-hour OCREVUS infusion time, 
dosed twice yearly (six-monthly), is now approved for eligible people 
with RMS or PPMS in the U.S and EU. 
   OCREVUS is approved in 95 countries across North America, South America, 
the Middle East, Eastern Europe, as well as in Australia, Switzerland, 
the United Kingdom and the European Union (EU). 
   About ENSPRYNG(R) (satralizumab) 
   ENSPRYNG, which was designed by Chugai, a member of the Roche Group, is 
a humanised monoclonal antibody that targets interleukin-6 (IL-6) 
receptor activity. The cytokine IL-6 is believed to be a key driver in 
NMOSD, triggering the inflammation cascade and leading to damage and 
disability. ENSPRYNG was designed using novel recycling antibody 
technology which, compared to conventional technology, allows for longer 
duration of the antibody and subcutaneous dosing every four weeks. 
   Positive Phase III results for ENSPRYNG, as both monotherapy and in 
combination with baseline immunosuppressive therapy, suggest that IL-6 
inhibition is an effective therapeutic approach for NMOSD. The Phase III 
clinical development programme for ENSPRYNG includes two studies: 
SAkuraStar and SAkuraSky. 
   ENSPRYNG is currently approved in 18 countries, including the United 
States, Canada, Japan and Switzerland. Applications are under review 
with numerous regulators. 
   ENSPRYNG has been designated as an orphan drug in the U.S., Europe and 
   About Roche in Neuroscience 
   Neuroscience is a major focus of research and development at Roche. Our 
goal is to pursue groundbreaking science to develop new treatments that 
help improve the lives of people with chronic and potentially 
devastating diseases. 
   Roche is investigating more than a dozen medicines for neurological 
disorders, including spinal muscular atrophy, multiple sclerosis, 
neuromyelitis optica spectrum disorder, Alzheimer's disease, 
Huntington's disease, Parkinson's disease, Duchenne muscular dystrophy 
and autism spectrum disorder. Together with our partners, we are 
committed to pushing the boundaries of scientific understanding to solve 
some of the most difficult challenges in neuroscience today. 
   About Roche 
   Roche is a global pioneer in pharmaceuticals and diagnostics focused on 
advancing science to improve people's lives. The combined strengths of 
pharmaceuticals and diagnostics under one roof have made Roche the 
leader in personalised healthcare -- a strategy that aims to fit the 
right treatment to each patient in the best way possible. 
   Roche is the world's largest biotech company, with truly differentiated 
medicines in oncology, immunology, infectious diseases, ophthalmology 
and diseases of the central nervous system. Roche is also the world 
leader in in vitro diagnostics and tissue-based cancer diagnostics, and 
a frontrunner in diabetes management. 
   Founded in 1896, Roche continues to search for better ways to prevent, 
diagnose and treat diseases and make a sustainable contribution to 
society. The company also aims to improve patient access to medical 
innovations by working with all relevant stakeholders. More than thirty 
medicines developed by Roche are included in the World Health 
Organization Model Lists of Essential Medicines, among them life-saving 
antibiotics, antimalarials and cancer medicines. Moreover, for the 
twelfth consecutive year, Roche has been recognised as one of the most 
sustainable companies in the Pharmaceuticals Industry by the Dow Jones 
Sustainability Indices (DJSI). 
   The Roche Group, headquartered in Basel, Switzerland, is active in over 
100 countries and in 2020 employed more than 100,000 people worldwide. 
In 2020, Roche invested CHF 12.2 billion in R&D and posted sales of CHF 
58.3 billion. Genentech, in the United States, is a wholly owned member 
of the Roche Group. Roche is the majority shareholder in Chugai 
Pharmaceutical, Japan. For more information, please visit 
   All trademarks used or mentioned in this release are protected by law. 
   [1] Minion 9, single 
   [2] No reference linking within document please! 
   [3] Lorem ipsum 
   Roche Group Media Relations 
   Phone: +41 61 688 8888 / e-mail: 
Dr. Nicolas Dunant          Patrick Barth 
 Phone: +41 61 687 05 17     Phone: +41 61 688 44 86 
Dr. Daniel Grotzky          Karsten Kleine 
 Phone: +41 61 688 31 10     Phone: +41 61 682 28 31 
Nina Mählitz           Nathalie Meetz 
 Phone: +41 79 327 54 74     Phone: +41 61 687 43 05 
Dr. Barbara von Schnurbein 
 Phone: +41 61 687 89 67 
Roche Investor Relations 
Dr. Karl Mahler                               Jon Kaspar Bayard 
 Phone: +41 61 68-78503                        Phone: +41 61 68-83894 
 e-mail: mailto:karl.mahler@roche.com          e-mail: mailto:jon_kaspar.bayard@roche.com 
 karl.mahler@roche.com                         jon_kaspar.bayard@roche.com 
--------------------------------------------  ------------------------------------------- 
Dr. Sabine Borngräber                    Dr. Bruno Eschli 
 Phone: +41 61 68-88027                        Phone: +41 61 68-75284 
 e-mail: mailto:sabine.borngraeber@roche.com   e-mail: mailto:bruno.eschli@roche.com 
 sabine.borngraeber@roche.com                  bruno.eschli@roche.com 
--------------------------------------------  ------------------------------------------- 
Dr. Birgit Masjost                            Dr. Gerard Tobin 
 Phone: +41 61 68-84814                        Phone: +41 61 68-72942 
 e-mail: mailto:birgit.masjost@roche.com       e-mail: mailto:gerard.tobin@roche.com 
 birgit.masjost@roche.com                      gerard.tobin@roche.com 
--------------------------------------------  ------------------------------------------- 
Investor Relations North America 
Loren Kalm                                    Dr. Lisa Tuomi 
 Phone: +1 650 225 3217                        Phone: +1 650 467 8737 
 e-mail: mailto:kalm.loren@gene.com            e-mail: mailto:tuomi.lisa@gene.com 
 kalm.loren@gene.com                           tuomi.lisa@gene.com 
--------------------------------------------  ------------------------------------------- 
   -- 08042020_MR_AAN Curtain Raiser_EN 

(END) Dow Jones Newswires

April 08, 2021 01:00 ET (05:00 GMT)

All news about ROCHE HOLDING AG
04/16ROCHE HOLDING AG  : quaterly sales release
04/16ROCHE  : Multiple Sclerosis Drug Shows Benefit In Late-Stage Trials
04/16ROCHE  :  New Data for Genentech's Ocrevus (ocrelizumab) Reinforce Significant B..
04/16ROCHE  : New data for Roche's OCREVUS (ocrelizumab) reinforce significant benefi..
04/16PRESS RELEASE  : New data for Roche's OCREVUS -2-
04/16PRESS RELEASE  : New data for Roche's OCREVUS (ocrelizumab) reinforce significan..
04/15ROCHE  : Germany Aims Wider Rollout Of Regeneron, Roche's COVID-19 Drug
04/15ROCHE  : FDA Approves Xolair (omalizumab) Prefilled Syringe for Self-Injection A..
04/15NOVARTIS  : Signs Technology Transfer Deal To Produce Ingredient For Potential C..
04/15ROCHE  : Spinal Muscular Atrophy Drug Shows Continued Effect After Two Years in ..
More news
Sales 2021 60 169 M 65 356 M 65 356 M
Net income 2021 14 761 M 16 034 M 16 034 M
Net cash 2021 5 234 M 5 685 M 5 685 M
P/E ratio 2021 17,6x
Yield 2021 3,05%
Capitalization 266 B 289 B 289 B
EV / Sales 2021 4,33x
EV / Sales 2022 4,08x
Nbr of Employees 101 465
Free-Float 82,6%
Duration : Period :
Roche Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 353,44 CHF
Last Close Price 309,20 CHF
Spread / Highest target 42,6%
Spread / Average Target 14,3%
Spread / Lowest Target -6,21%
EPS Revisions
Managers and Directors
Severin Schwan Chief Executive Officer & Executive Director
Alan Hippe Chief Financial & Information Technology Officer
Christoph Franz Chairman
Urs Jaisli Chief Compliance Officer
André S. Hoffmann Vice Chairman
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING AG0.06%289 376
JOHNSON & JOHNSON3.09%422 260
PFIZER INC.2.15%209 739
NOVARTIS AG-3.73%197 072
MERCK & CO., INC.-5.29%194 049
ABBVIE INC.0.71%188 642